title: RespiGam: an RSV immune globulin.
abstract: Respiratory syncytial virus immune globulin has been shown to prevent or attenuate RSV lower respiratory tract infection in infants under 24 months of age with BPD or who were born prematurely (< or = 35 weeks gestation). The use of RSV-IG is expensive. The estimated average cost of prophylaxis for a season is $4,000 to $5,000 per infant. Because of the cost of RSV-IG, and because viral transmission is possible when any blood product is administered, careful consideration of which children should receive RSV-IG is warranted.
authors.affiliation: University of North Carolina Hospitals, Department of Pharmacy, in Chapel Hill, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Oertel
mesh_terms: D002675:Child, Preschool; D004347:Drug Interactions; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D018357:Respiratory Syncytial Virus Infections / Q000628:therapy*
chemical_list: D016756:Immunoglobulins, Intravenous; C098685:respiratory syncytial virus immune globulin intravenous